SAN DIEGO, March 1, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced it will present a poster at the ASCO Genitourinary Cancers Symposium in San Francisco this week, reporting additional results from a Phase I/IIa clinical trial of Apoptone® (HE3235), its anticancer drug candidate being developed for prostate cancer. Apoptone is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to induce cell death (apoptosis) in animal models of prostate and breast cancers.
Presenting the poster is the lead investigator of the study, R. Bruce Montgomery, M.D., Associate Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine. The study is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium (PCCTC).
| Title: | HE3235, a synthetic adrenal hormone, in castrate resistant prostate cancer (CRPC) |
| patients: Clinical Phase I/II trial results | |
| Poster No.: | 235 |
| Presentation Time: | Saturday, March 6, 12:30 p.m. to 2:00 p.m. |
About Harbor BioSciences, Inc.
Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone, in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Harbor BioSciences please visit www.harborbiosciences.com.